Charles Rhodes, MD
Cardiovascular Disease · Las Vegas, NVNPI 1437105855
Payments from drug & device makers
Across 173 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boehringer Ingelheim$304
- Merck$282
- Sanofi-aventis U.S. LLC$247
- Abbott$241
- Johnson & Johnson$170
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 71 | $1,059 |
| Boehringer Ingelheim | 7 | $304 |
| Merck | 13 | $282 |
| Sanofi-aventis U.S. LLC | 15 | $247 |
| Abbott | 6 | $241 |
| Johnson & Johnson | 11 | $170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $156 |
| Acist Medical Systems, Inc. | 1 | $150 |
| Amgen | 7 | $120 |
| Lexicon Pharmaceuticals, Inc. | 5 | $119 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Medtronic(2 entities) | 2 | $68 |
| Impulse Dynamics (USA) Inc. | 2 | $64 |
| Amarin Pharma, Inc. | 4 | $55 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Pfizer | 3 | $47 |
| Tactile Systems Technology Inc | 2 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| AstraZeneca | 2 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,355 in reported general payments places this provider in the 50th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 367 | $427,339 |
| EntrestoSacubitril/Valsartan | 243 | $334,111 |
| XareltoRivaroxaban | 128 | $163,407 |
| Repatha SureclickEvolocumab | 99 | $82,009 |
| MultaqDronedarone Hcl | 42 | $63,083 |
| Praluent PenAlirocumab | 31 | $34,116 |
| BrilintaTicagrelor | 46 | $30,634 |
| FarxigaDapagliflozin Propanediol | 21 | $20,159 |
| VerquvoVericiguat | 16 | $10,882 |
| Rosuvastatin Calcium | 705 | $10,117 |
| Ezetimibe | 461 | $10,098 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,943 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $6,066 |
| Amiodarone Hcl | 289 | $5,860 |
| Atorvastatin Calcium | 403 | $3,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $47 | $427,339367 claims |
| NovartisEntresto | $1,059 | $334,111243 claims |
| Johnson & JohnsonXarelto | $170 | $163,407128 claims |
| Sanofi-aventis U.S. LLCMultaq | $247 | $63,08342 claims |
| AstraZenecaBrilinta, Farxiga | $24 | $50,79367 claims |
| MerckVerquvo | $282 | $10,88216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
- Arjun GururajLas Vegas$399K
- Navid KazemiLas Vegas$156K
- Branavan UmakanthanLas Vegas$109K
- Sanjay MalhotraLas Vegas$101K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Rafael ValenciaLas Vegas$52K
- Salvador BorromeoLas Vegas$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.